The sensational news on Sunday 4 November was the TRITON trial which demonstrated that in 13,608 STEMI/non STEMI patients treated invasively and followed for a year with prasugrel versus clopodigrel, the stronger prasugrel led to significantly less myocardal infarctions, yet had no incidence on strokes or deaths.
Stent thrombosis was halved by prasugrel compared to clopidogrel. However severe bleeding was increased by 32% by prasugrel which may hamper its general use in interventional therapy for (N)STEMI patients.
Our mission: To reduce the burden of cardiovascular disease.